Back to Search
Start Over
Concurrent administration of adjuvant chemotherapy and radiotherapy after breast-conserving surgery enhances late toxicities: long-term results of the ARCOSEIN multicenter randomized study
- Source :
- International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2006, 65 (2), pp.324-32. ⟨10.1016/j.ijrobp.2005.12.020⟩, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, undefined or unknown publisher, 2006, 65 (2), pp.324-32. 〈10.1016/j.ijrobp.2005.12.020〉
- Publication Year :
- 2006
- Publisher :
- HAL CCSD, 2006.
-
Abstract
- International audience; PURPOSE: In 1996, a multicenter randomized study was initiated that compared sequential vs. concurrent adjuvant chemotherapy (CT) with radiation therapy (RT) after breast-conserving surgery (ARCOSEIN study). After a median follow-up of 6.7 years (range, 4.3-9 years), we decided to prospectively evaluate the late effects of these 2 strategies. METHODS AND MATERIALS: A total of 297 patients from the 5 larger participating institutions were asked to report for a follow-up examination. Seventy-two percent (214 patients) were eligible for evaluation of late toxicity. After breast-conserving surgery, patients were treated either with sequential treatment with CT first followed by RT (Arm A) or CT administered concurrently with RT (Arm B). In all patients, CT regimen consisted of mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), and cyclophosphamide (500 mg/m2), 6 cycles (Day 1 to Day 21). Conventional RT was delivered to the whole breast by administration of a 2 Gy per fraction protocol to a total dose of 50 Gy (+/- boost to the primary tumor bed). The assessment of toxicity was blinded to treatment and was graded by the radiation oncologist, according to the LENT/SOMA scale. Skin pigmentation was also evaluated according to a personal 5-points scoring system (excellent, good, moderate, poor, very poor). RESULTS: Among the 214 evaluable patients, 107 were treated in each arm. The 2 populations were homogeneous for patient, tumor, and treatment characteristics. Subcutaneous fibrosis (SF), telangectasia (T), skin pigmentation (SP), and breast atrophy (BA) were significantly increased in Arm B. No statistical difference was observed between the 2 arms of the study concerning Grade 2 or higher pain, breast edema, or lymphedema. No deaths were caused by late toxicity. CONCLUSION: After breast-conserving surgery, the concurrent use of CT with RT is significantly associated with an increase incidence of Grade 2 or greater late side effects.
- Subjects :
- Cancer Research
MESH: Combined Modality Therapy
MESH : Antineoplastic Combined Chemotherapy Protocols
medicine.medical_treatment
MESH : Aged
MESH : Prospective Studies
Skin Pigmentation
Segmental
MESH : Breast Neoplasms
Mastectomy, Segmental
[ SDV.CAN ] Life Sciences [q-bio]/Cancer
030218 nuclear medicine & medical imaging
0302 clinical medicine
Antineoplastic Combined Chemotherapy Protocols
Breast-conserving surgery
MESH : Female
Prospective Studies
MESH: Radiotherapy Dosage
MESH : Cyclophosphamide
Radiation oncologist
Mastectomy
Adjuvant
MESH: Aged
Radiation
MESH: Middle Aged
MESH : Neoplasm Recurrence, Local
MESH : Radiotherapy Dosage
MESH : Chemotherapy, Adjuvant
Radiotherapy Dosage
MESH : Adult
Middle Aged
Combined Modality Therapy
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
Oncology
Local
Chemotherapy, Adjuvant
MESH: Chemotherapy, Adjuvant
030220 oncology & carcinogenesis
MESH : Fluorouracil
Female
MESH: Skin Pigmentation
Fluorouracil
MESH: Mitoxantrone
MESH: Neoplasm Recurrence, Local
medicine.drug
Adult
medicine.medical_specialty
Cyclophosphamide
Urology
Breast Neoplasms
[SDV.CAN]Life Sciences [q-bio]/Cancer
03 medical and health sciences
Breast cancer
medicine
Chemotherapy
Humans
MESH : Middle Aged
Radiology, Nuclear Medicine and imaging
MESH: Mastectomy, Segmental
MESH : Mastectomy, Segmental
Subcutaneous fibrosis
Aged
MESH: Humans
business.industry
MESH : Humans
MESH: Cyclophosphamide
MESH: Adult
medicine.disease
MESH: Prospective Studies
Surgery
Radiation therapy
Regimen
Neoplasm Recurrence
MESH : Mitoxantrone
Neoplasm Recurrence, Local
MESH : Skin Pigmentation
Mitoxantrone
MESH : Combined Modality Therapy
business
MESH: Female
MESH: Fluorouracil
MESH: Breast Neoplasms
Subjects
Details
- Language :
- English
- ISSN :
- 03603016
- Database :
- OpenAIRE
- Journal :
- International Journal of Radiation Oncology-Biology-Physics, International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2006, 65 (2), pp.324-32. ⟨10.1016/j.ijrobp.2005.12.020⟩, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, International Journal of Radiation Oncology*Biology*Physics / International Journal of Radiation Oncology Biology Physics; International Journal of Radiation Oncology Biology & Physics, undefined or unknown publisher, 2006, 65 (2), pp.324-32. 〈10.1016/j.ijrobp.2005.12.020〉
- Accession number :
- edsair.doi.dedup.....25be0419cc14b24a5b4ce81014704436